Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Prostate Adenocarcinoma 1Pregnancy Complications 1Leiomyoma 1Endometriosis 1Adenocarcinoma 1

Interventions

pembrolizumab 4Oxaliplatin 4zolbetuximab 2camrelizumab 2apatinib 2S 1 (combination) 2trastuzumab deruxtecan 1tislelizumab 1tepotinib 1relugolix 1lenvatinib 1durvalumab 1dabrafenib 1cemiplimab 1cabazitaxel 1alpha-2'-deoxythioguanosine 1X-Rays 1Vinorelbine 1Surveys and Questionnaires 1Ramucirumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Radiation 1Proton Therapy 1Pemetrexed 1Paclitaxel 1Nivolumab 1Leucovorin 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma × relugolix × Clear all
NCT07302451 2026-01-06

REDI-CaP

National Cancer Institute, Naples

Phase 2 Active not recruiting
50 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡